Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Layilin is a type I transmembrane protein and a cell surface receptor with a domain homologous to C-type lectin carbohydrate-recognition regions[1][2]. It serves as a receptor for hyaluronan, a major extracellular matrix glycosaminoglycan, playing a role in cell–extracellular matrix adhesion, cell migration, actin cytoskeleton reorganization, and immune cell function[1][2]. Layilin interacts with talin and possibly other ERM family proteins, linking the extracellular environment to the cytoskeleton and participating in dynamic membrane ruffling events and immune modulation. Expression of LAYN has been correlated with prognosis and immune infiltration in different cancers, especially colorectal and gastric cancer, and may be important in the regulation of tumor-associated macrophages, dendritic cells, and T cell exhaustion[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Layilin (LAYN).